Amlodipine and Weight Gain
Yes, amlodipine can cause apparent weight gain, but this is primarily due to peripheral edema (fluid retention) rather than true fat accumulation. The edema is dose-dependent, occurs in up to 10.8% of patients at 10 mg daily, and is significantly more common in women (14.6%) than men (5.6%) 1.
Mechanism of Edema
Amlodipine causes peripheral edema through direct vasodilation of precapillary arterioles without corresponding venodilation, leading to increased capillary hydrostatic pressure and fluid extravasation into interstitial tissues 2. This is not responsive to diuretics because it's a hemodynamic rather than volume-overload phenomenon 3.
The edema:
- Is dose-related: 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg daily 1
- Typically affects the lower extremities (pedal/ankle edema)
- Is usually mild to moderate and often transient 4
- Represents fluid accumulation that can manifest as weight gain on the scale
Clinical Management Algorithm
When peripheral edema occurs on amlodipine:
First-line: Reduce the dose - Cutting from 10 mg to 5 mg significantly reduces edema risk (from 10.8% to 3.0%) 1, 3
Second-line: Add or increase ACE inhibitor or ARB - These agents reduce amlodipine-induced edema by promoting venodilation and balancing the hemodynamic effects, even though they don't affect postural vasoconstriction 2, 3
Third-line: Switch to lercanidipine or lacidipine - These second-generation dihydropyridines have lower edema rates, with lacidipine ranking lowest for peripheral edema among all calcium channel blockers 3, 5
Alternative: Switch to non-dihydropyridine CCB (verapamil/diltiazem) if no heart failure with reduced ejection fraction 3
Important Caveats
Do not use diuretics to treat amlodipine-induced edema - they are ineffective because the mechanism is increased capillary pressure, not volume overload 3. The ACC/AHA guidelines specifically note this is "dose-related pedal edema" that is "more common in women than men" 6.
Approximately 37% of edema cases in patients on amlodipine may be unrelated to the drug itself 7, so evaluate for other causes (heart failure, venous insufficiency, renal disease, hypoalbuminemia) before automatically attributing it to amlodipine.
The "weight gain" listed in FDA labeling occurs in <1% of patients 1 and likely represents the measurable weight increase from fluid accumulation rather than metabolic weight gain. True metabolic weight gain from amlodipine is not a recognized phenomenon.
Gender Considerations
Women experience 2.6 times higher rates of edema (14.6% vs 5.6% in men) at therapeutic doses 1. This sex difference should inform dosing decisions, particularly when initiating therapy in female patients.